StreetInsider.com News Articles

Lobe Sciences names new CMO, hires market-making firm

Tue, 20 Oct 2026 08:30:15 -0400

Lobe Sciences Ltd. (CSE: LOBE)(OTCQB: LOBEF) announced the appointment of Tracy L. Goeken, M.D., as Chief Medical Officer, effective October 20, 2026.

Dr. Goeken most recently served as Chief Medical Officer at Linical, a global clinical research organization, where he led clinical development strategy and medical oversight across multiple therapeutic areas. He brings more than 20 years of experience in clinical development, regulatory strategy, and medical affairs, with prior roles at Somahlution, Nuron Biotech, and Pharm-Olam International.

His background includes contributions to regulatory approvals across FDA and EMA jurisdictions, FDA Orphan Drug and Fast Track designation efforts, and EMA acceptance of MRI

Lobe Sciences names new CMO, hires market-making firm

Tue, 20 Oct 2026 08:30:15 -0400

Lobe Sciences Ltd. (CSE: LOBE)(OTCQB: LOBEF) announced the appointment of Tracy L. Goeken, M.D., as Chief Medical Officer, effective October 20, 2026.

His background includes contributions to regulatory approvals across FDA and EMA jurisdictions, FDA Orphan Drug and Fast Track designation efforts, and EMA acceptance of MRI

Lobe Sciences Appoints Tracy L. Goeken, M.D., as Chief Medical Officer

Tue, 20 Oct 2026 08:30:00 -0400

VANCOUVER, BC / ACCESS Newswire / October 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company developing therapies for neurological conditions and rare diseases, today announced the appointment of Tracy L. Goeken, M.D., as Chief Medical Officer, effective October 20, 2026. Dr. Goeken most recently served as Chief Medical Officer at Linical, a global clinical research organization, where he led clinical development strategy and medical oversight of clinical trials across multiple therapeutic areas.

"We are delighted to welcome Dr. Goeken to Lobe as we prepare for the

Lobe Sciences Appoints Tracy L. Goeken, M.D., as Chief Medical Officer

Tue, 20 Oct 2026 08:30:00 -0400

"We are delighted to welcome Dr. Goeken to Lobe as we prepare for the

Lobe Sciences Appoints Tracy L. Goeken, M.D., as Chief Medical Officer

Tue, 20 Oct 2026 08:30:00 -0400

"We are delighted to welcome Dr. Goeken to Lobe as we prepare for the

Lobe Sciences Appoints Tracy L. Goeken, M.D., as Chief Medical Officer

Tue, 20 Oct 2026 08:30:00 -0400

"We are delighted to welcome Dr. Goeken to Lobe as we prepare for the

Lobe Sciences adds ex-BMO Capital Markets banker to its board

Wed, 14 Oct 2026 08:01:24 -0400

Lobe Sciences Ltd. (CSE: LOBE, OTCQB: LOBEF, FWB: LOBE.F) has appointed Annette Grimaldi to its board of directors, according to a company statement.

Grimaldi brings 35 years of life sciences investment banking experience, including roles advising on public and private financings, mergers and acquisitions, and strategic transactions. From 2009 to 2024, she served as Managing Director and Head of Life Sciences Investment Banking at BMO Capital Markets. She previously held senior roles at Jefferies & Company and SG Cowen Securities Corporation, and began her career at Goldman Sachs in New York and Tokyo.

Grimaldi currently serves on the board of Delsona Therapeutics

Lobe Sciences adds ex-BMO Capital Markets banker to its board

Wed, 14 Oct 2026 08:01:24 -0400

Lobe Sciences Ltd. (CSE: LOBE, OTCQB: LOBEF, FWB: LOBE.F) has appointed Annette Grimaldi to its board of directors, according to a company statement.

Grimaldi currently serves on the board of Delsona Therapeutics

Lobe Sciences Appoints Annette Grimaldi, Former Head of Life Sciences Investment Banking at BMO Capital Markets, to Board of Directors

Wed, 14 Oct 2026 08:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / October 14, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with significant unmet medical needs, today announced the appointment of Annette Grimaldi to its Board of Directors.

Ms. Grimaldi is a veteran life sciences investment banker with 35 years of experience advising CEOs, CFOs and boards on public and private financings, mergers and acquisitions, and strategic transactions. From 2009 to 2024, she established, built and led the life sciences practice at BMO Capital Markets

Lobe Sciences Appoints Annette Grimaldi, Former Head of Life Sciences Investment Banking at BMO Capital Markets, to Board of Directors

Wed, 14 Oct 2026 08:00:00 -0400

Lobe Sciences Appoints Annette Grimaldi, Former Head of Life Sciences Investment Banking at BMO Capital Markets, to Board of Directors

Wed, 14 Oct 2026 08:00:00 -0400

Lobe Sciences Appoints Annette Grimaldi, Former Head of Life Sciences Investment Banking at BMO Capital Markets, to Board of Directors

Wed, 14 Oct 2026 08:00:00 -0400

Lobe Sciences Announces Proposed Capital Markets Initiatives to Support Planned Growth

Thu, 08 Oct 2026 08:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / October 8, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, today announced its intention to strengthen its capital markets presence through independent market-making services, a significant expansion of investor relations and public relations activities, and the addition of an experienced U.S.-based capital markets professional to its Board of Directors.

The planned initiatives are intended to broaden awareness of Lobe's pharmaceutical programs, support trading liquidity and strengthen the Company's ability to pursue its next

Lobe Sciences Announces Proposed Capital Markets Initiatives to Support Planned Growth

Thu, 08 Oct 2026 08:00:00 -0400

The planned initiatives are intended to broaden awareness of Lobe's pharmaceutical programs, support trading liquidity and strengthen the Company's ability to pursue its next

Lobe Sciences Announces Proposed Capital Markets Initiatives to Support Planned Growth

Thu, 08 Oct 2026 08:00:00 -0400

The planned initiatives are intended to broaden awareness of Lobe's pharmaceutical programs, support trading liquidity and strengthen the Company's ability to pursue its next

Lobe Sciences Announces Proposed Capital Markets Initiatives to Support Planned Growth

Thu, 08 Oct 2026 08:00:00 -0400

The planned initiatives are intended to broaden awareness of Lobe's pharmaceutical programs, support trading liquidity and strengthen the Company's ability to pursue its next

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit

Mon, 14 Sep 2026 23:00:00 -0400

● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16

● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses

● Lobe to exhibit throughout the summit, September 15-17, alongside senior discovery, clinical and business development leaders from major pharmaceutical companies

VANCOUVER, BC / ACCESS Newswire / September 14, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company developing

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit

Mon, 14 Sep 2026 23:00:00 -0400

● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16

● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses

● Lobe to exhibit throughout the summit, September 15-17, alongside senior discovery, clinical and business development leaders from major pharmaceutical companies

VANCOUVER, BC / ACCESS Newswire / September 14, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company developing

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit

Mon, 14 Sep 2026 23:00:00 -0400

● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16

● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses

● Lobe to exhibit throughout the summit, September 15-17, alongside senior discovery, clinical and business development leaders from major pharmaceutical companies

VANCOUVER, BC / ACCESS Newswire / September 14, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company developing

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit

Mon, 14 Sep 2026 23:00:00 -0400

● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16

● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses

● Lobe to exhibit throughout the summit, September 15-17, alongside senior discovery, clinical and business development leaders from major pharmaceutical companies

VANCOUVER, BC / ACCESS Newswire / September 14, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company developing

Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Mon, 14 Sep 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 14, 2026) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe" or the "Company") is pleased to announce its participation in the upcoming 3^rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel. Dr. David Kideckel, Ph.D., MBA, Chief Financial Officer of Lobe Sciences, will participate as a Featured Company and will hold one-on-one meetings with interested investors and capital markets professionals.

"This is a valuable opportunity to introduce Lobe Sciences to Canadian and U.S. investors. We are advancing innovative therapies for neurological and

Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Mon, 14 Sep 2026 08:00:00 -0400

"This is a valuable opportunity to introduce Lobe Sciences to Canadian and U.S. investors. We are advancing innovative therapies for neurological and

Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Mon, 14 Sep 2026 08:00:00 -0400

"This is a valuable opportunity to introduce Lobe Sciences to Canadian and U.S. investors. We are advancing innovative therapies for neurological and

Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Mon, 14 Sep 2026 08:00:00 -0400

"This is a valuable opportunity to introduce Lobe Sciences to Canadian and U.S. investors. We are advancing innovative therapies for neurological and

Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™

Mon, 18 Nov 2024 19:00:00 -0400

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™
Once issued, this patent will provide additional coverage for psilocin mucate compositions

VANCOUVER, British Columbia & STUART, Fla.--(BUSINESS WIRE)-- Lobe Sciences, Ltd. ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma, Inc. (“Alera” or “Alera Pharma”), biopharmaceutical companies focused on developing products to treat diseases with significant unmet medical needs, today announce that a second patent allowance for Conjugated Psilocin™ has been received. The patent application is entitled “Stable Psilocin Salts, Esters, and Conjugates and Uses Thereof”. This application contains claims